(Q34431300)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Maria Trojano

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Heinz Wiendl

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Shibeshih Belachew

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Fabio Pellegrini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Radhika N Patel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Annie Zhang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Christophe Hotermans

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

TYSABRI Observational Program (TOP) Investigators

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Ludwig Kappos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

English

0 references

publication date

14 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neurology, Neurosurgery and Psychiatry

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

1190-1197

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

8 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215289

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215289

Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215289

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215289

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215289

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215289

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215289

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1136%2FJNNP-2013-306936

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1136%2FJNNP-2013-306936

Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1136%2FJNNP-2013-306936

Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24532785

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24532785

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/JNNP-2013-306936

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

PubMed publication ID

24532785

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532785%20AND%20SRC:MED&resulttype=core&format=json